Investigating the effect of empagliflozin on renal events in non-diabetic chronic kidney disease patients with and without proteinuria. A double-blind placebo-controlled randomized clinical trial study

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 458 人开始时间: 待定最近更新: 2022年11月21日

适应症

试验速览

暂无简介。

•Patients over 18 years old
•Patients with 20=eGFR=75 mL/min/1.73m2 (calculated by MDRD formula) at the first visit

•Dominant or autosomal recessive polycystic kidney disease, lupus nephritis or vasculitis with anti-neutrophil cytoplasmic antibody (ANCA)
•Received cytotoxic therapy, immunosuppressive therapy, or other immunologic therapy for primary or secondary renal disease within 6 months prior to the first visit
•Organ transplant history
•Blood pressure less than 90/60 mmHg
•Treatment with a sodium glucose cotransporter (SGLT 2) inhibitor within 8 weeks before the first visit or previous drug intolerance
•Frequent UTI
•Type 1 and 2 diabetes
•Class (NYHA) IV congestive heart failure at first visit
•Myocardial infarction, unstable angina, stroke and transient ischemic attack (TIA) within 12 weeks before the first visit
•Cardiovascular interventions such as CABG, PCI and valve replacement or repair within 12 weeks before the first visit
•Conditions such as malignancies where the patient does not have a good prognosis based on the clinical judgment of the researcher
•Active malignancy at the first visit
•Liver failure (AST and ALT more than three times normal and total bilirubin more than twice normal)
•Women prone to pregnancy who do not use contraceptive methods
•Pregnancy and breastfeeding
•Candida infection and low hygiene

发起方